Should US Insulins Be Treated As Biologics?
Draft Bill Favors ANDA Route For Insulins
Against a backdrop of continued outcry over insulin costs in the US and the looming FDA-imposed transition of insulins to biologic status in early 2020, legislators and manufacturers alike are still lobbying for alternative approaches to the essential diabetes treatment.
